Jaguar Health, Inc. (JAGX): Consensus Estimates and Trading Data

In the past 52-week period, shares of Jaguar Health, Inc. (NASDAQ:JAGX) have moved within the range of $0.10 to $1.52. On the stock’s most recent trading day, the company’s shares ended the regular session at $0.14, which is 90.79% higher than its 52-week high.

Jaguar Health, Inc. (JAGX) has demonstrated a 20-day simple moving average (SMA) of 8.03%, and a 50-day SMA of -7.91%. This public company’s current market capitalization stands at $14.92 million.

Analyzing Consensus Estimates, Sales Revenue and Net Income

When thinking about buying shares in a public company, it is useful to gauge the average enthusiasm level of Wall Street analysts for that specific stock. According to the latest data, the consensus recommendation for Jaguar Health, Inc. (JAGX) is Outperform.

When it comes to quarterly financial results, publicly-traded companies usually post earnings and revenue figures that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Jaguar Health, Inc. (JAGX) delivered a 31.45% surprise with its net revenue.

Ownership at Jaguar Health, Inc. (JAGX), According to Most Recent SEC Filings

Additionally, according to the most recent 13F filing from Jaguar Health, Inc. (JAGX), there were 4 new positions totaling 2,532,018 shares of the company’s stock. There were 2 sold out positions, on the other hand, totaling 26,477 shares.

Short, Medium and Long Term Indicators

By looking at a stock’s average trade volume – in the short, medium, and long terms – we can gain a better understanding of investor sentiment and trading activity. Jaguar Health, Inc. (JAGX) has had a 20-day average volume of 3,090,540 shares, with an average of 20% of short term indicators pointed at Buy.

The stock’s 50-day average volume has been 3,071,260 shares, with an average of 25% of medium term indicators pointing toward Sell. Finally, its 100-day average volume is 2,397,654 shares with 67% of long-term indicators pointing to Sell.